Svb Leerink Comments on AxoGen, Inc’s Q1 2020 Earnings (NASDAQ:AXGN)

AxoGen, Inc (NASDAQ:AXGN) – Svb Leerink issued their Q1 2020 EPS estimates for AxoGen in a research report issued on Monday, October 14th. Svb Leerink analyst R. Newitter anticipates that the medical equipment provider will earn ($0.09) per share for the quarter. Svb Leerink also issued estimates for AxoGen’s Q2 2020 earnings at ($0.09) EPS, Q3 2020 earnings at ($0.10) EPS and Q4 2020 earnings at ($0.10) EPS.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.09. The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.77 million. AxoGen had a negative return on equity of 16.73% and a negative net margin of 26.91%. The firm’s revenue was up 29.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.09) earnings per share.

Several other research firms have also recently issued reports on AXGN. ValuEngine raised AxoGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. BTIG Research dropped their price target on AxoGen to $21.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Cantor Fitzgerald dropped their price target on AxoGen from $30.00 to $21.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. BidaskClub downgraded shares of AxoGen from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. Finally, William Blair downgraded shares of AxoGen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $31.00.

NASDAQ AXGN opened at $11.83 on Wednesday. The stock has a market capitalization of $458.89 million, a P/E ratio of -21.91 and a beta of 0.17. AxoGen has a 1 year low of $10.91 and a 1 year high of $39.33. The business’s fifty day moving average is $13.82 and its two-hundred day moving average is $18.42. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.87 and a current ratio of 8.70.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Inc. increased its stake in shares of AxoGen by 86.3% in the second quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,180 shares during the last quarter. Stonebridge Capital Advisors LLC acquired a new position in shares of AxoGen in the second quarter worth $59,000. Aperio Group LLC acquired a new position in shares of AxoGen in the second quarter worth $77,000. Quantamental Technologies LLC increased its stake in shares of AxoGen by 188.5% in the second quarter. Quantamental Technologies LLC now owns 4,128 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 2,697 shares during the last quarter. Finally, Valeo Financial Advisors LLC increased its stake in shares of AxoGen by 17.8% in the third quarter. Valeo Financial Advisors LLC now owns 6,607 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 1,000 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Quentin S. Blackford bought 15,535 shares of the business’s stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $14.01 per share, with a total value of $217,645.35. Following the purchase, the director now directly owns 25,098 shares in the company, valued at $351,622.98. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Karen L. Zaderej bought 75,000 shares of the business’s stock in a transaction on Friday, August 9th. The shares were purchased at an average cost of $13.50 per share, for a total transaction of $1,012,500.00. Following the completion of the purchase, the chief executive officer now owns 593,280 shares in the company, valued at $8,009,280. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 107,535 shares of company stock worth $1,389,672. Company insiders own 6.77% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: What is a management fee?

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.